Tesamorelin

What Is Tesamorelin?

Tesamorelin is a synthetic 44-amino-acid peptide analog of human growth hormone-releasing hormone (GHRH, also called GRF). It corresponds to the full-length 44-residue GHRH(1-44) sequence with a single N-terminal modification: the tyrosine residue at position 1 carries a trans-3-hexenoyl group on its alpha-amine.

This acyl modification is the key structural distinction from native GHRH and is described in the published literature as the basis for tesamorelin’s improved metabolic stability in research model systems.

In published research literature, tesamorelin is studied in the context of GHRH-receptor agonism, downstream growth hormone (GH) and insulin-like growth factor-1 (IGF-1) axis signaling, and metabolic endpoints in clinical and preclinical lipodystrophy and hepatic-fat research models.

Tesamorelin in Plain Language

A non-technical overview of what tesamorelin is, what researchers have studied it for, what the evidence suggests, and what cannot be claimed about it. For research and educational purposes only.

At a glance

Tesamorelin is a lab-made peptide that prompts the body to release its own growth hormone in a more natural, pulsed pattern. In research, scientists study it for its ability to reduce deep belly fat (called visceral fat) while preserving muscle, and for related effects on the liver in conditions like fatty liver disease.

A pharmaceutical version of this molecule (sold under a different brand name) is FDA-approved for a specific medical condition and is manufactured and distributed entirely separately from the research chemical sold here; the two are not interchangeable. The compound sold here is a research chemical, not a pharmaceutical or therapeutic product, and is not for human or animal use.

What it is

Tesamorelin is a synthetic 44-amino-acid peptide that is structurally analogous to growth hormone-releasing hormone (GHRH), a natural signaling molecule made in the hypothalamus. The key engineering feature is a small chemical modification at the “front end” of the peptide (a trans-3-hexenoyl group on the first amino acid).

Published research describes this modification as protecting tesamorelin from a fast-acting enzyme called DPP-4 that normally inactivates natural GHRH within minutes. The longer functional life is what makes tesamorelin useful as a research probe of the GHRH→growth-hormone→IGF-1 axis.

Researchers commonly study tesamorelin in laboratory contexts related to pituitary signaling, growth-hormone release dynamics, body-composition biology (visceral fat), and liver-fat metabolism.

Research areas being investigated

• GHRH-receptor pharmacology: Studied in cell and pituitary research models for activation of the GHRH receptor (GHRHR) and downstream cAMP signaling.
• Growth-hormone / IGF-1 axis research: Used to probe the pulsatile release of growth hormone from pituitary somatotrophs and the resulting hepatic IGF-1 response.
• Visceral fat biology: Investigated in body-composition research, originally in HIV-associated lipodystrophy populations.
• Hepatic lipid / NAFLD research: Examined in clinical research for changes in liver-fat fraction by MR spectroscopy.
• Peptide-engineering / DPP-4 resistance research: Used as a comparator against unmodified GHRH in protease-stability and pharmacokinetic studies.

What the research suggests so far

Animal / preclinical findings. Preclinical work has characterized tesamorelin’s extended half-life relative to native GHRH, its activity at the GHRH receptor, and its effects on the GH-IGF-1 axis in rodent and primate model systems.

Cell / lab findings. In cell and biochemistry experiments, tesamorelin has been described as a selective GHRH-receptor agonist with substantial resistance to DPP-4-mediated cleavage. These findings inform hypotheses about peptide-engineering strategies more broadly.

Human findings. Tesamorelin has a more substantial published human research base than most peptides BioChain offers. As the pharmaceutical product the FDA-approved pharmaceutical formulation® (Theratechnologies), it has been studied in randomized Phase III trials in HIV-associated lipodystrophy populations, where reductions in visceral adipose tissue, trunk fat, and waist circumference were reported alongside increases in IGF-1.

Subsequent randomized human research in HIV-positive cohorts has examined reductions in hepatic fat fraction by MR spectroscopy. These data are tied to a specific clinical population and a specific dosing regimen used in registration trials and do not generalize to non-pharmaceutical-grade research material, to other populations, or to other intended uses.

BioChain USA’s product is research-use-only material, not the FDA-approved the FDA-approved pharmaceutical formulation® drug, and is not represented as equivalent to it.

Limitations of the evidence. Outside the HIV-associated lipodystrophy registration program and the related liver-fat work, the long-term safety and efficacy of tesamorelin in other populations remains poorly characterized. Published reviewers continue to call for additional research in non-HIV NAFLD populations and other metabolic contexts before broader conclusions can be drawn.

Research-grade material is not equivalent to a finished pharmaceutical product in formulation, sterility, or oversight.

Research relevance

Tesamorelin is most often discussed in research involving GHRH-receptor pharmacology, growth-hormone release dynamics, IGF-1 axis biology, visceral adipose tissue research in lipodystrophy contexts, and hepatic lipid / NAFLD model systems. It is also commonly cited in peptide-engineering research as a benchmark example of N-terminal modification for DPP-4 resistance.

Many of the human findings come from a specific clinical context (HIV-associated lipodystrophy) and a specific FDA-approved formulation; they do not, on their own, justify generalized claims about research-grade material.

What cannot be claimed about tesamorelin (research-grade material)

• It cannot be claimed to treat, cure, heal, or prevent any human or animal condition.
• It cannot be claimed to be equivalent to or a substitute for the FDA-approved pharmaceutical formulation® or any other FDA-approved pharmaceutical product.
• It cannot be claimed to reduce belly fat, treat obesity, treat fatty liver, or improve body composition in customers.
• It cannot be claimed to slow aging, increase muscle mass, or improve athletic performance.
• It cannot be claimed to be safe or effective for human or veterinary use.
• It cannot be represented as a dietary supplement.

Summary

Tesamorelin is a synthetic GHRH analog protected from rapid DPP-4 degradation by an N-terminal trans-3-hexenoyl modification. It is studied in research on GHRH-receptor pharmacology, growth-hormone and IGF-1 axis signaling, visceral adipose tissue biology, and hepatic lipid metabolism. A pharmaceutical-grade version of the molecule is FDA-approved (the FDA-approved pharmaceutical formulation®) for a specific clinical indication in HIV-associated lipodystrophy; that approval applies to the finished drug product manufactured under regulatory oversight, not to research-grade chemical material.

BioChain USA’s tesamorelin is sold strictly as a research-use-only chemical for laboratory investigation. It is not intended for human consumption, medical use, or veterinary use.

Short version

Tesamorelin is a synthetic GHRH analog used in research on the growth-hormone / IGF-1 axis and visceral fat biology. A pharmaceutical version of the molecule is FDA-approved for a specific HIV-related condition; that approval does not extend to research-grade material, which is not a drug. Sold for research and laboratory use only.

Source notes

• Russo SC, et al. Efficacy and safety of tesamorelin in people with HIV on integrase inhibitors. AIDS (London, England), 2024. (PubMed PMID: 38905488.)
• Falutz J, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med, 2007, Phase III randomized clinical trial.
• Stanley TL, et al. Effects of tesamorelin on hepatic fat and visceral fat in HIV-infected patients with abdominal adiposity. JAMA, 2014, randomized clinical trial.
• Stanley TL, et al. Effect of tesamorelin on liver fat and histology in HIV-infected patients with NAFLD. Lancet HIV, 2019, randomized clinical trial.
• Tesamorelin, LiverTox monograph, NCBI Bookshelf NBK548730, clinical safety review.
• Tesamorelin (DB08869), DrugBank monograph (regulatory and pharmacologic reference).
• Falutz J, et al. Long-term safety and effects of tesamorelin in HIV-associated lipodystrophy: meta-analysis, review of pooled randomized data.

Source types: entries 1, 2, 3 are randomized clinical trials in HIV-related populations; entries 4, 5 are regulatory / monograph references; entry 6 is a pooled-data review. All clinical findings refer to the FDA-approved pharmaceutical formulation, not research-grade material.

SEO meta description

Tesamorelin (research-grade) is a synthetic GHRH analog studied in research on the GH / IGF-1 axis, visceral fat biology, and hepatic lipid metabolism. Research-use only.

Reminder. BioChain USA sells tesamorelin strictly as a research-use-only chemical for qualified laboratory and educational use. It is not the FDA-approved the FDA-approved pharmaceutical formulation® drug and is not intended for human consumption, medical treatment, veterinary treatment, diagnosis, prevention, or cure of disease.

Certificate of Analysis (COA)

• COA provided where available for the specific batch shipped.
• The batch COA is the authoritative reference for analytical methods, purity data, and lot-specific testing for that shipment.
• COA information is batch-specific and is not interchangeable between lots.

Frequently Asked Questions